Patent applications for novel pain therapeutics have declined steadily in number between 2008 and 2012
Patent applications for novel pain therapeutics declined steadily in number from 4970 in 2008 to 3492 in 2012, an average annual decrease of 8%, as limited understanding of pain pathophysiology continues to hinder drug development in this arena, according to business intelligence provider GBI Research.
The company’s latest report states that patent applications for pain treatments between 2008 and 2012 were dominated by Big Pharma, including Sanofi, Novartis and Merck, which submitted 169, 162 and 142 applications, respectively.
However, according to GBI Research, the global pain treatment market is dominated by opioids and steroidal anti-inflammatory drugs, with no novel products currently able to challenge these products’ efficacy in treating moderate to severe acute pain.
Furthermore, despite the significant unmet needs for more effective therapies in other pain subtypes, such as chronic and neuropathic pain, owing to their rising prevalence, the factors underpinning these subtypes are complex and poorly understood.
However, this limited knowledge is being countered by technological advances and significant research efforts, with new insights translating into an expanding pool of novel therapeutic targets.
GBI Research states that the overall pain therapy pipeline is exceptionally large and moderately diverse, with a number of molecules boasting different mechanisms of action from those seen in the current market landscape. This offers a high probability of producing strong market entrants in the near future.
Indeed, among the 111 first-in-class pipeline products available for strategic consolidations, some have shown promising preclinical evidence and significant potential to become game-changing treatments, representing high-reward investments.